Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

SARS-CoV-2-infected adipocytes drive adipose inflammation and hepatocyte lipid accumulation.

López CAM., Parra M., Freiberger RN., Jarmoluk P., Sviercz FA., Quarleri J.

Laboratory Study on Face & Skin, published in Front Immunol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Immunol (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42421964
DOI
10.3389/fimmu.2026.1848780

Abstract (original English)

Obesity and fatty liver may worsen COVID-19 outcomes, but the mechanism by which adipose tissue infection contributes to liver injury is unclear. We aimed to determine whether SARS-CoV-2 infection of human adipocytes promotes inflammation and hepatic lipid accumulation, and to identify the underlying mechanisms. Mesenchymal stem cell-derived human adipocytes were infected with Wuhan SARS-CoV-2 strain. Cell-surface ACE2 expression was measured in adipocytes. Viral replication and infectious titers were measured, and adipocyte morphology, cytokine/adipokine secretion, and lipid metabolism gene expression were analyzed. Culture supernatants from infected adipocytes were then applied to Huh7.5 hepatocytes to evaluate steatosis and fibrogenic activation. SARS-CoV-2 productively infected adipocytes, which express cell-surface ACE2, leading to hypertrophy, increased IL-6 secretion, a higher leptin/adiponectin ratio, and lipid droplet accumulation. The infectious virus was released into the supernatants. However, neutralization with anti-Spike antibodies or UV-C inactivation abolished this effect, indicating that hepatocyte lipid accumulation depended on infectious virus rather than on soluble adipocyte-derived mediators alone. Adipose tissue can serve as a source of infectious SARS-CoV-2 that promotes hepatic steatosis and fibrogenic activation, suggesting a mechanism by which obesity

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAdipocytesHepatocytesSARS-CoV-2Lipid MetabolismCOVID-19InflammationAngiotensin-Converting Enzyme 2Fatty LiverAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research